Smoking cessation in pregnancy: Why, how, and what next...

Clinical Obstetrics and Gynecology

Volumn 51, Issue 2, 2008, Pages 419-435

  Crawford, Julie T ^a   Tolosa, Jorge E ^a,b,d   Goldenberg, Robert L ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Global Network for Perinatal and Reproductive Health   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bupropion; Cessation; Nicotine replacement therapy; Pregnancy; Smoking; Tobacco use; Varenicline

Indexed keywords

AMFEBUTAMONE; BIOCHEMICAL MARKER; CLONIDINE; MACLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NALOXONE; NALTREXONE; NICOTINE; NORTRIPTYLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VARENICLINE;

ABNORMAL DREAMING; ALTERNATIVE MEDICINE; BEHAVIOR; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COUNSELING; DROWSINESS; FATIGUE; FETUS RISK; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; INTERVENTION STUDY; LOW BIRTH WEIGHT; MORBIDITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PREGNANCY; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIMARY PREVENTION; PUERPERIUM; RELAPSE; REVIEW; SAFETY; SCREENING; SMOKING; SMOKING CESSATION; THERAPY EFFECT; XEROSTOMIA;

BEHAVIOR THERAPY; BENZAZEPINES; BUPROPION; COUNSELING; FEMALE; HUMANS; NICOTINE; PREGNANCY; PREGNANCY OUTCOME; QUINOXALINES; SMOKING; SMOKING CESSATION;

EID: 43249084022     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31816fe9e9     Document Type: Review

References (65)

1. Mackay J, Eriksen M. The Tobacco Atlas. Geneva: World Health Organization; 2003.
2. National Institutes of Health State-of-the-Science Conference Statement. Tobacco use: prevention, cessation, and control. Ann Intern Med. 2006;145:839-844.
3. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2003. Natl Vital Stat Rep. 2005;54:14.
4. CDC. Cigarette smoking among adults - United Sates. MMWR. 2004;53:427-431.
5. Department of Health and Human Services. Women and Smoking: A report of the Surgeon General. Rockville: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001.
6. Warren CW, Jones NR, Eriksen MP, et al. Patterns of global tobacco use in young people and implications for future chronic disease burdens in adults. Lancet. 2006;367:749-753.
7. American Heart Association. Heart and stroke statistical 2006 Update.
8. Center for Disease Control and Prevention. Women and Smoking: a report of the Surgeon General. MMWR. 2002;52:1-30.
9. Andres RL, Day MC. Perinatal complications associated with maternal tobacco use. Semin Neonatol. 2000;5:231-241.
10. Burton GJ, Palmer ME, Dalton KJ. Morphometric differences between the placental vasculature of non-smokers, smokers, and ex-smokers. Br J Obstet Gynaecol. 1989;96:907.
11. Lumley J, Oliver SS, Chamberlain C, et al. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2005.
12. Sorensen G, Goldberg R, Ockene J, et al. Heavy smoking among a sample of employed women. Am J Prev Med. 1992;8:207-214.
13. COMMIT Research Group. Community Intervention Trial for Smoking Cessation (COMMIT): I. Cohort results from a four-year community intervention. Am J Public Health. 1995;85:183-192.
14. Dominguez-Rojas V, de Juanes-Pardo JR, Astasio-Arbiza P, et al. Spontaneous abortion in a hospital population: are tobacco and coffee intake risk factors? Eur J Epidemiology. 1994;10:665.
15. Armstrong BG, McDonald AD, Sloan M. Cigarette, alcohol, and coffee consumption and spontaneous abortion. Am J Public Health. 1992;82:85.
16. Hadley CB, Main DM, Gabbe SG. Risk factors for preterm rupture of the fetal membranes. Am J Perinatology. 1990;7:374.
17. Harger JH, Hsing AW, Tuomala RE, et al. Risk factors for preterm premature rupture of fetal membranes: a multicenter case-control study. Am J Obstet Gynecol. 1990;163:130-137.
18. Raymond EG, Mills JL. Placental abruption. Maternal risk factors and associated fetal conditions. Acta Obstet Gynecol Scand. 1993;72:633.
19. Ananth CV, Savitz DA, Luther ER. Maternal cigarette smoking as a risk factor for placental abruption, placenta previa, and uterine bleeding in pregnancy. Am J Epidemiology. 1996;144:881.
20. Chelmow D, Andrew DE, Baker ER. Maternal smoking and placenta previa. Obstet Gynecol. 1996;87:703.
21. Spinillo A, Capuzzo E, Nicola SE, et al. Factors potentiating the smoking-related risk of fetal growth retardation. Br JObstet Gynaecol. 1994;101:954.
22. McDonald AD, Armstrong BG, Sloan M. Cigarette, alcohol, and coffee consumption and prematurity. Am J Public Health. 1992;82:87.
23. Hammoud AO, Bujold E, Sorokin Y, et al. Smoking in pregnancy revisited: findings from a large population-based study. Am J Obstet Gynecol. 2005;192:1856-1862.
24. Kolas T, Nakling J, Salvesen KA. Smoking during pregnancy increases the risk of preterm births among parous women. Acta Obstet Gynecol Scand. 2000;79:644-648.
25. Department of Health and Human Services. The Health Benefits of Smoking Cessation: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990.
26. Anonymous. Medical care expenditures attributable to cigarette smoking during pregnancy-United States. MMWR. 1997;46:1048-1050.
27. Wang X, Zuckerman B, Pearson C, et al. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA. 2002;287:195.
28. de la Chica RA, Ribas I, Giraldo J, et al. Chromosomal instability in amniocytes from fetuses of mothers who smoke. JAMA. 2005;293:1212.
29. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2006.
30. Fiore MC. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. Treating tobacco use and dependence: a U.S. Public Health Service Report. JAMA. 2000;283:3244-3254.
31. Lieberman E, Gremy I, Lang JM, et al. Low birthweight at term and timing of fetal exposure to maternal smoking. Am J Public Health.1994;84:1127.
32. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2000.
33. American Psychiatric Association. Practice guidelines for the treatment of patients with nicotine dependence. Am J Psychiatry. 1996;153:1.
34. Fiore MC, Baily WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD: US Dept of Health and Human and Services; 2000.
35. Smoking Cessation During Pregnancy. ACOGTechnical Bulletin. #316, October 2005.
36. Windsor RA, Woodby LA, Miller T, et al. Effectiveness of AHCPR practice recommendations and patient education methods for pregnancy smokers in Medicaid maternity care. Am J Obstet Gynecol. 2000;182:68-75.
37. Mullen PD, Carbonari JP, Tabak ER, et al. Improving disclosure of smoking by pregnant women. Am J Obstet Gynecol. 1991;165:409-413.
38. Melvin CL, Dolan-Mullen P, Windsor RA, et al. Recommended cessation counseling for pregnant women who smoke: a review of the evidence. Tob Control. 2000;9(suppl III):iii80-iii84.
39. Lancaster T, Stead LF. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2005.
40. Scott WJ, Mcllvain H. Interactive software: an educational/behavioural approach to smoking cessation for pregnant women and their families. Tob Control. 2000;9(suppl III): iii56-iii57.
41. Cinciripini PM, McClure JB, Wetter DW, et al. An evaluation of videotaped vignettes for smoking cessation and relapse prevention during pregnancy: the Very Important Pregnant Smokers (VIPS) program. Tob Control. 2000;9(suppl III): iii61-iii63.
42. Stead LF, Lancaster T. Group behaviour therapy programs for smoking cessation. Cochrane Database Syst Rev. 2002.
43. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
44. Marks JS, Koplan JP, Hogue CJ, et al. A cost-benefit/cost-effectiveness analysis of smoking cessation for pregnant women. Am J Prev Med. 1990;6:282-289.
45. Orleans CT, Barker DC, Kaufman NJ, et al. Helping pregnant smokers quit: meeting the challenge in the next decade. Tob Control. 2000;9(suppl III):iii6-iii11.
46. Lancaster T, Stead AF. Individual behavioral counseling for smoking cessation. Cochrane Database Syst Rev. 2005.
47. Donatelle RJ, Prows SL, Champeau D, et al. Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: significant other supporter (SOS) program. Tob Control. 2000;9(suppl III):iii67-iii69.
48. Hey K, Perera R. Competitions and incentives for smoking cessation. Cochrane Database Syst Rev. 2005.
49. Benowitz NL, Dempsey DA, Goldenberg RL, et al. The use of pharmacotherapies for smoking cessation during pregnancy. Tob Control. 2000;9(suppl III):iii91-iii94.
50. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2005.
51. Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. Lancet. 2005;365:1843-1854.
52. Morales-Suarez MM, Bille C, Christensen K, et al. Smoking habits, nicotine use, and congenital malformations. Obstet Gyneocol. 2006;107:51-57.
53. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321-327.
54. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. AJOG. 2005;192:953-936.
55. Hale T. Medications and Mother's Milk. 9th ed. Amarillo Texas: Pharmasoft Publishing; 2000.
56. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006;296:47-55.
57. Jorenby DE, Taylor H, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA. 2006;296:56-63.
58. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation. JAMA. 2006;296:64-71.
59. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, Varenicline, for smoking cessation. Arch Intern Med. 2006; 166:1571-1577.
60. White AR, Rampes H, Ernst E. Acupuncture for smoking cessation. Cochrane Database Syst Rev. 2005.
61. Abbot NC, Stead LF, White AR, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev. 2000.
62. Russell TV, Crawford MA, Woodby LL. Measurements for active cigarette smoke exposure in prevalence and cessation studies: why simply asking pregnant women isn't enough. Nicotine Tob Res. 2004;6:S141-S151.
63. Windsor RA, Li CQ, Boyd NR, et al. The use of significant reduction rates to evaluate health education methods for pregnant smokers. Health Educ Behav. 1999;26:648-662.
64. Secker-Walker RH, Vacek PM. Infant birth weight as a measure of harm reduction during smoking cessation trials in pregnancy. Health Educ Behav. 2002;29:557-569.
65. Hajek P, Stead LF, West R, et al. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2005.